WO2012166909A1 - Compositions et procédés pour traitement des troubles ou maladies de la régulation de la respiration - Google Patents

Compositions et procédés pour traitement des troubles ou maladies de la régulation de la respiration Download PDF

Info

Publication number
WO2012166909A1
WO2012166909A1 PCT/US2012/040195 US2012040195W WO2012166909A1 WO 2012166909 A1 WO2012166909 A1 WO 2012166909A1 US 2012040195 W US2012040195 W US 2012040195W WO 2012166909 A1 WO2012166909 A1 WO 2012166909A1
Authority
WO
WIPO (PCT)
Prior art keywords
ketodoxapram
solvate
composition
subject
enantiomeric purity
Prior art date
Application number
PCT/US2012/040195
Other languages
English (en)
Inventor
James C. Mannion
Scott L. Dax
Richard Woodward
Vita Ozola
Original Assignee
Galleon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galleon Pharmaceuticals, Inc. filed Critical Galleon Pharmaceuticals, Inc.
Publication of WO2012166909A1 publication Critical patent/WO2012166909A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • compositions and. Methods for Treating Breathing Control Disorders or Diseases
  • Normal control of breathing is a complex process that in v olves, in part, the body's interpretation and response to chemical stimuli such as carbon dioxide, pH and oxygen levels in blood, tissues and the brain. Breathing control is also affected by other factors such as wakefulness (i.e., whether the patient is awake or sleeping), emotion, posture and vocalization.
  • respirator ⁇ ' control centers that interpret various feedforward and feedback signals that affect respiration and issues commands to the muscles that perform the work of breathing. Key muscle groups are located in the abdomen, diaphragm, pharynx and thorax.
  • Sensors located centrally and peripherally then provide input to the brain's central respiration control areas that enables response to changing metabolic requirements.
  • C0 2 carbon dioxide levels
  • Increased C0 2 levels signal the body to increase breathing rate and depth, resulting in higher blood oxygen levels and subsequent lower blood C0 2 levels.
  • low CO ? levels can result in periods of hyponea (decreased breathing) or, in the extreme case, apnea (no breathing) since the stimulation to breathe is diminished. This is what happens w r hen a person hyperventilates.
  • apneas central, mixed or obstructive; where the breathing repeatedly stops for 10 to 60 seconds
  • Secondary loss of breathing control may be due to chronic cardiopulmonary diseases (e.g., heart failure, chronic bronchitis, emphysema, and
  • ⁇ - impending respiratory failure ⁇ excessive weight (e.g., obesity-hypoventilation syndrome), certain drugs (e.g., anesthetics, sedatives, anxiolytics, hypnotics, alcohol, and narcotic analgesics and/or factors that affect the neurological system (e.g., stroke, rumor, trauma, radiation damage, and ALS).
  • drugs e.g., anesthetics, sedatives, anxiolytics, hypnotics, alcohol, and narcotic analgesics and/or factors that affect the neurological system (e.g., stroke, rumor, trauma, radiation damage, and ALS).
  • chronic obstructive pulmonary diseases where the body is exposed to chronically high levels of carbon dioxide, the body adapts to the lower pH by a kidiiey mediated retention of bicarbonate, which has the effect of partially neu tralizing the CCVpH respiratory stimulation.
  • the patient is unable to mount a normal
  • Sleep disordered breathing is an example of where abnormalities in the control of breathing lead to a seriou s and prevalent disease in humans.
  • Sleep apnea is characterized by frequent periods of no or partial breathing.
  • Key factors that contribute to these apneas include anatomical factors (such as obesity), decreased hypercapnic and hypoxic ventilatory responses (e.g., decreased response to high carbon dioxide and low oxygen levels, respectively) and loss of "wakefulness" (e.g., drive to pharyngeal dilator muscles).
  • Apneic events result in hypoxia (and the associated oxidative stress) and eventually severe cardiovascular consequences (high blood pressure, stroke, heart attack).
  • Racemic l -ethy ⁇ -4-(2-(moiphilin- -yl)efhyf)-33-diphenyl-pym)lid.in- -one (commonly known as doxapram) is a known respiratory stimulant, marketed, under the name of DopramTM.
  • doxapram Doxapram lias a strong, dose-dependent effect on stimulating respiration (breathing) in animals (Ward & Franko, 1962, Fed. Proc. 21 :325).
  • doxapram causes an increase in tidal volume and respiratory rate.
  • Doxapram is used in intensive care settings to stimulate respiration in patients with respiratory failure and to suppress shivering after surgery.
  • Doxapram is also useful for treating respiratory depression in patients who have taken excessive doses of opioid drugs such as buprenorphine and fail to respond, adequately to treatment with naloxone.
  • opioid drugs such as buprenorphine and fail to respond, adequately to treatment with naloxone.
  • use of doxapram in the medical setting is hampered by side effects, such as high blood pressure, panic attacks, tachycardia (rapid heart rate), tremor, convulsions, sweating, vomiting and the sensation of "air hunger.”
  • Doxapram may not be used in patients with coronary heart disease, epilepsy and high blood pressure.
  • the C-4 carbon in the structure of doxapram is a chiral center, and thus there are two distinct enantiomers associated with this molecule: the (+)-enantiomer and the (— )-enantionier.
  • the concept of enantiomers is well known to those skilled in the art.
  • the two enantiomers have the same molecular formula and identical chemical connectivity but opposite spatial "handedness.”
  • the two enantiomers are a mirror image of each other but are not superimposable.
  • Chiral molecules have the unique property of causing a rotation in the original plane of vibration of plane-polarized light.
  • Individual enantiomers are able to rotate plane-polarized light in a clockwise (dextrorotary; the (+)-enantiomer) or counter clockwise (levorotatory; the (— )-enantiomer) manner.
  • the pure enantiomers rotate plane-polarized light by the same number of degrees but in opposite directions.
  • racemic mixture or a "racemate” is a term used, to indicate the mixture of essentially equal quantities of enantiomeric pairs. Racemic mixtures are devoid of appreciable optical activity due to the mutually opposing optical activities of the individual enantiomers. Apart from their interaction with polarized light, enantiomers may differ in their phy sical, chemical and pharmacology activities, but such differences between enantiomers are largely unpredictable. Recent attempts have been made to develop pure enantiomers as new drags, based on previously marketed racemic drags (Nunez et al., 2009, Curr. Med. Chem. 16(16):2064-74).
  • Doxapram is marketed and medically used, as a racemate, Doxapram has been previously separated into its pure enantiomers using methods such as chirai high-performance chromatography (Chankvetadze et al., 1996, J. Pharm. Biomed. Anal. 14: 1295-1303; Thunberg et al., 2002, J. Pharm. Biomed. Anal. 27:431 -39), and chirai capillary electrophoresis (Christians & Hoizgrabe, 2001. J. Chromat. A 91 1 :249-57).
  • the enantiomers of doxapram were predicted to have identical oral bioavailability (Moda et al, 2007, Bioorg. Med. Chem. 15:7738- 45).
  • Ketodoxapram (4-[2-( l-ethyl-5-oxo-4,4-diphenyl-pyrrolidin-3-yl)- ethyl]-morphoiin ⁇ 3 ⁇ one) was found to be one of the major metabolites of doxapram in adults and newborn infants (Robson & Prescott, 1979, Br. J. Clin. Pharmacol, 7:81 - 87; Aranda et al., 1987, Pediatr. Res. 21 :357). Ketodoxapram was shown to have comparable pharmacological potency to doxapram and cause overt CNS stimulation in lambs (Bairam et al, 1991 , Resp. Phys. 86:345-54). Ketodoxapram appears to have fewer adverse effects but slightly shorter effect on baseline minute ventilation than doxapram (Bairam et al., 1990, Ped. Res. 28(2): 142-46).
  • the invention includes a composition comprising (-f-)-ketodoxapram or a solvate thereof, wherein the composition is essentially free of (— )-ketodoxapram or a solvate thereof,
  • the (-H)-ketodoxapram or solvate thereof has enantiomeric purity of at least about 95%, In another embodiment, the
  • (+)-ketodoxapram or solvate thereof has enantiomeric purity of at least about 97%
  • the (+)-ketodoxapram or solvate thereof has enantiomeric purity of at least about 99%.
  • the composition further comprises at least one pharmaceutically acceptable carrier.
  • the invention also includes a method of preventing or treating a breathing control disorder or disease in a subject in need thereof.
  • the method comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and (+)-ketodoxapram or a solvate thereof, wherein the composition is essentially free of (— )-ketodoxapram or a solvate thereof.
  • the (+)-ketodoxapram or solva te thereof has at least about 95% enantiomeric purity. In another embodiment, the (+)-ketodoxapram or solvate thereof has at least about 97% enantiomeric purity. In yet another embodiment, the (- )-ketodoxapram or solvate thereof has at least about 99% enantiomeric purity. In yet another embodiment, the breathing control disorder or disease is selected from the group consisting of respiratory depression, sleep apnea, apnea of prematurity, obesity-hypoventiiation syndrome, primary alveolar hypoventilation syndrome, dyspnea, altitude sickness, hypoxia, and liypercapnia.
  • the respiratory depression is caused by an anesthetic, a sedative, an anxiolytic agent, a hypnotic agent, alcohol or a narcotic.
  • the subject is further administered a composition comprising at least one additional compound useful for treating the breathing control disorder or disease.
  • the at least one additional compound is selected from the group consisting of an opioid, sedative, anesthetic, acetazolamide, almitrine, theophylline, caffeine, methyl progesterone, a serotinergic modulator, a cannabinoid, and an ampakine.
  • the composition is administered in conjunction with the use of a mechanical ventilation device or positive airway pressure device on the subject.
  • the subject is a mammal.
  • the mammal is a human
  • the composition is administered to the subject by an inhalational, topical, oral, buccal, rectal, vaginal, intramuscular, subcutaneous, transdermal, intrathecal or intravenous route.
  • the invention also includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof.
  • the method comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and (+)-ketodoxapram or a solvate thereof, wherein the composition is essentially free of (— )-ketodoxapram or a solvate thereof.
  • the (+)-ketodoxapram or solvate thereof has at least about 95% enantiomeric purity. In another embodiment, the (+)-ketodoxapram or solvate thereof has at least about 97% enantiomeric purity. In yet another embodiment, the (+)-ketodoxapram or solvate thereof has at least about 99% enantiomeric purity. In yet another embodiment, the subject is further administered a composition comprising at least one additional compound useful for preventing destabilization of or stabilizing the breathing rhythm.
  • the at least one additional compound is selected from the group consisting of an opioid, sedative, anesthetic, acetazolamide, almitrine, theophylline, caffeine, methyl progesterone, a serotonergic modulator, a cannabinoid, and an ampakine.
  • the composition is administered in conjunction with the use of a mechanical ventilation device or positive airway pressure device on the subject.
  • the subject is a mammal.
  • the mammal is a human.
  • the composition is administered to the subject by an inhalational, topical, oral, buccal, rectal, vaginal, intramuscular, subcutaneous, transdermal, intrathecal or intravenous route.
  • the invention also includes a method of preparing (H-)-ketodoxapram.
  • the method comprises reacting (R)-l-ethyl-4-(2-iodoethyl)-3,3-diphenylpyrrolidin-2- one with morpholin-3-one in a solvent to yield (-H)-doxapram.
  • morpholin-3-one is pretreated with a strong base to form the corresponding anion of morpholin-3-one.
  • the strong base comprises sodium hydride.
  • the solvent comprises ⁇ , ⁇ -dimethylformamide (DMF).
  • (R)-l -ethyl- 4-(2-iodoethyl)-3,3-diphenylpyrrolidin-2-one is prepared from (R)-2-( l- ethylpyrrolidin-3-yl)-2,2-diphenylacetic acid.
  • (R)-2-(l- ethylpyrrolidin-3-yl)-2,2-diphenylacetic acid is contacted with acetic anhydride and sodium iodide to yield (R)-l-ethy3-4-(2-iodoethyl)-3,3-diphenylpyrro3idio-2-one.
  • (R)-2-(l-ethylpyrrolidin-3-yl)-2,2 ⁇ diphenyIacetic acid is prepared by hydrolyzing (R)-2-(l -ethylpyrrolidin-3-yl)-2,2-diphenylacetonitrile.
  • the hydrolyzing comprises treatment with a sulfuric acid solution and a hydrobromic acid solution.
  • (R)-2 ⁇ (l ⁇ ethylpyi olidin-3-yl)-2,2-diphenylacetonitrile is prepared by reacting (R)-3-chloro-l - ethylpyrrolidine with an anion of diphenylacetonitrile.
  • (R.)-3-chloro-l-ethylpyrrolidine is prepared by chlorinating (S)-l-ethylpyrrolidin-3-ol.
  • the chlorinating comprises treating (S)-l-ethylpyrrolidin- 3-ol with thionyi chloride.
  • (S)-l-ethylpyrrolidin-3-ol is prepared by reducing (S)-l -acetylpyrrolidin-3-yl acetate.
  • (S)- l-acetylpyrroIidin-3-yl acetate is prepared by acetylating (S)-3- hydroxypyrrolidine.
  • preparing (R)-2-(l -ethylpyrrolidin- 3-yl)-2,2-diphenylacetonitriie comprises: converting (R)-l-ethy3pyrroiidin-3-ol to a nucleophilically labile hydroxyl derivative, and reacting the derivative with an anion of diphenylacetonitrile to yield (R)-2-(l-ethylpyrrolidin-3-yl)-2,2- diphenylacetonitrile.
  • Figure 1 is a graph illustrating the chiral HPLC trace for the first eluting peak derived from the resolution of ketodoxapram.
  • Figure 2 is a graph illustrating the chiral HPLC trace for the second eluting peak derived from the resolution of ketodoxapram.
  • Figure 3 is a graph illustrating the chiral HPLC trace for racemic ketodoxapram.
  • Vehicle and (R)-4-[2-(l-ethyl-5-oxo-4,4- diphenyi-pyrrolidin-3-yl ⁇ -eihyl]-morpholin-3-one ( 1, 3, and 10 mg/kg) were administered intravenously to urethane anesthetized rats.
  • the present invention relates to the unexpected discovery that the (+)-enantiomer of ketodoxapram displays most or all the desired beneficial pharmacological activity associated with the racemic ketodoxapram.
  • the present invention relates to the unexpected discover ⁇ ' that the (— )-enantiomer of ketodoxapram is essentially devoid of activity in stimulating ventilation or reversing respiratory depression, and moreover produces a number of acute side effects that were not detected as the same doses with (+)- ketodoxapram, such as hunching posture, increased urination and defecation, clonic movements and other seizure-like behaviors, pronounced drops in mean arterial blood pressure, and production of cardiac arrhythmias and death.
  • the present invention includes a pharmaceutical composition
  • a pharmaceutical composition comprising the (+)-enantiomer of (4-[2-(l -ethyl-5-oxo-4,4-diphenyl-pyrrolidin-3-yl)- ethylj-morpholin-3-one), also known as (+)-ketodoxapram, or a solvate thereof and a pharmaceutically acceptable carrier, wherein the composition is essentially free of (— -)-ketodoxapram or a solvate thereof.
  • the present invention also includes a method of preparing (+)- ketodoxapram, wherein (+)-ketodoxapram is essentially free of (—) -ketodoxapram.
  • the present inv ention also includes a method of treating a breathing control disease or disorder in a subject in need thereof.
  • the breathing control disease or disorder includes, but is not limited to, respiratory depression (induced by anesthetics, sedatives, anxiolytic agents, hypnotic agents, alcohol, and analgesics), sleep apnea, apnea of prematurity, obesity -hypoventilation syndrome, primary alveolar hypoventilation syndrome, dyspnea, altitude sickness, hypoxia, hypercapnia and chronic obstructive pulmonary disease (COPD).
  • respiratory depression induced by anesthetics, sedatives, anxiolytic agents, hypnotic agents, alcohol, and analgesics
  • sleep apnea apnea of prematurity
  • obesity -hypoventilation syndrome primary alveolar hypoventilation syndrome
  • dyspnea altitude sickness
  • hypoxia hypoxia
  • the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising (+)-ketodoxapram or a solvate thereof, and a pharmaceutically acceptable carrier, wherein the composition is essentially tree of (— )-ketodoxapram or a solvate thereof.
  • the articles “a” and “an” refer to one or to more than one (i.e. to at least one) of the grammatical object of the article.
  • an element means one element or more than one element.
  • a “subject”, as used therein, can be a human or non-human mammal.
  • Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, canine, feline and murine mammals.
  • livestock and pets such as ovine, bovine, porcine, canine, feline and murine mammals.
  • the subject is human.
  • doxapram refers to l -ethyl-4-(2-(morphiiin- 4-yl)ethyl)-3,3-diphenyl-pyrrolidin-2-one, or a solvate thereof. Unless otherwise noted, “doxapram” refers to racemic doxapram, which comprises an essentially equimolar mixture of the two enantiomers of doxapram (the (+)-enantiomer and the (— )-enantiomer).
  • a "solvate" of a compound refers to a combination of the compound and at least one solvent.
  • the solvate comprises water.
  • the solvate comprises an organic solvent, such as, but not limited to, DMSO, ethanol, «-propanol or isopropanol.
  • the "(+)-doxapram” and “(— )-doxapram” enantiomers are defined in terms of the order in which they are eiuted from ehiral HPLC column, defined as: (a) a CHIKALPAK*" AY 20 ⁇ column, with 3cm internal diameter x 25cm length, using ethanol with 0.2% DMEA (dimethylet ykmine) and C0 2 as mobile phase, in a ratio of 15:85 (v/v), with a flow rate of 85 g/min, a column temperature of 35°C, and UV detection at 220 nm; or (b) a CHXRALPAK ® AY-H 5 ⁇ column, with 3cm internal diameter x 25cm length, using ethanol with 0.2% DMEA and CO ?
  • (+)-ketodoxapram and “(— Vketodoxapram” enantiomers are defined in terms of the corresponding (-t-)-doxapram and (—-)- doxapram.
  • (+)-Ketodoxapram has the same absolute stereochemistry as (+)- doxapram
  • (— )-ketodoxapram has the same absolute stereochemistry as (— -)- doxapram.
  • the nomenclature “(H-)-ketodoxapram” should not be construed to imply that this enantiomer rotates the vibrational plane of plane-polarized light in a clockwise manner under all possible combinations of solvent, temperature and concentration.
  • the term "enantiomeric purity" of a given enantiomer over the opposite enantiomer indicates the excess % of the given enantiomer over the opposite enantiomer, by mole. For example, in a mixture comprising about 80% of a given enantiomer and about 20% of the opposite enantiomer, the enantiomeric purity of the given enantiomer is about 60%.
  • the term "essentially free of as applied to a given enantiomer in a mixture with the opposite enantiomer indicates that the enantiomeric purity of the given enantiomer is higher than about 80%, more preferably higher than about 90%, even more preferably higher than about 95%, even more preferably higher than about 97%, even more preferably higher than about 99%, even more preferably higher than about 99.5%, even more preferably higher than about 99.9%, even more preferably higher than about 99.95%, even more preferably higher than about 99.99%>.
  • Such purity determination may be made by any method known to those skilled in the art, such as chirai HPLC analysis or chiral electrophoresis analysis.
  • minute ventilation is a measure of breathing volume per unit time and is given herein as mL/min
  • pC0 2 is partial pressure of carbon dioxide (gas) in (arterial) blood measured in mmHg (millimeters of Hg units)
  • p0 2 is partial pressure of oxy gen (gas) in (arterial) blood measured in mmHg (millimeters of Hg units)
  • Sa0 2 is the percentage of oxygen saturation (dissolved oxygen gas) which correlates to the percentage of hemoglobin binding sites in the bloodstream occupied by oxygen.
  • ED 50 refers to the effective dose that produces a given effect in 50 % of the subjects.
  • a "disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal's health continues to deteriorate.
  • a disorder in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal's state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal's state of health.
  • an “effective amount” or “therapeutically effective amount” of a compound is that amount of compound which is sufficient to provide a beneficial effect to the subject to which the compound is administered.
  • the term to "treat,” as used herein, means reducing the frequency with which symptoms are experienced by a patient or subject or administering an agent or compound to reduce the severity with which sy mptoms are experienced.
  • treating a disease or disorder means reducing the frequency with which a symptom of the disease or disorder is experienced by a patient.
  • Disease and disorder are used interchangeably herein.
  • AEs adverse events
  • clonic movements and other seizure-like behaviors, pronounced drops in mean arterial blood pressure, production of cardiac arrhy thmias and death.
  • the term “about” will be understood by persons of ordinary skill in the art and will van' to some extent on the context in v/hich it is used.
  • the term “about” is meant to encompass variations of ⁇ 20% or ⁇ 10%, more preferably ⁇ 5%, even more preferably ⁇ 1%, and still more preferably ⁇ 0.1 % from the specified value, as such variations are appropriate to perform the disclosed methods.
  • the invention includes a composition comprising
  • (+)-ketodoxapram or a solvate thereof wherein the composition is essentially free of (— )-ketodoxapram or a solvate thereof.
  • the enantiomeric purity of the (+)-ketodoxapram or a solvate thereof is at least about 90%, In another embodiment, the enantiomeric purity of the (+)-ketodoxapram or a solvate thereof is at least about 95%. In yet another embodiment, the enantiomeric purity of the (+)-ketodoxapram or a solvate thereof is at least about 97%. In yet another embodiment, the enantiomeric purity of the (+)-ketodoxapram or a solvate thereof is at least about 99%. In yet another embodiment, the enantiomeric purity of the (-t-)-ketodoxapram or a solvate thereof is at least about 99.5%.
  • the enantiomeric purity of the (+)-ketodoxapram or a solvate thereof is at least about 99.9%. In yet another embodiment, the enantiomeric purity of the (+)-ketodoxapram or a solvate thereof is at least about 99.95%. In yet another embodiment, the enantiomeric purit of the (+)-ketodoxapram or a solvate thereof is at least about 99.99%. In yet another embodiment, the composition further comprises at least one pharmaceutical carrier.
  • Racemic ketodoxapram or a solvate thereof may be prepared using any of the methods disclosed in the chemical literature.
  • a non-limiting synthetic scheme is represented in Scheme 1.
  • ( ⁇ j-Ketodoxapram or a solvate thereof that is essentially free of ( ⁇ -)-ketodoxapram or a solvate thereof may he prepared by chiral resolution of racemic doxapram, using a method such as chiral chromatography (in a non-limiting example, chiral HPLC).
  • the (-i-)-enantiomer of ketodoxapram or a salt thereof may be prepared using from optically enriched or pure pyrroiidinol or hydroxyproline.
  • a non-limiting synthetic scheme is represented below.
  • the present invention includes a method of preparing (+)- ketodoxapram, comprising reacting (R)-l-ethyl-4-(2-iodoethyl)-3,3- diphenylpyrrolidin-2-one with morpholin-3-one in a solvent to yield (+)-doxapram.
  • morpholin-3-one is pretreated with a strong base.
  • the base comprises sodium hydride.
  • the solvent comprises ⁇ , ⁇ -dimethyiformamide (DMF).
  • (R) ⁇ 1 -ethyl-4-(2-iodoethyl)-3 ,3-diphenyfpyrrolidin-2-one is prepared from (R)-2-(l -ethylpyrrolidin-3-yl)-2,2-diphenylacetic acid.
  • (R)-2-(l-ethylpyrrolidin-3-yl)-2,2-diphenylacetic acid is contacted with acetic anhydride and sodium iodide to yield (R)-l-ethy3-4-(2-iodoethyl)-3,3- diphenylpyrrolidin-2-one.
  • (R)-2-(l-ethylpyrrolidin-3 -yl) ⁇ 2,2-diphenylacetic acid is prepared by hydrolyzing (R)-2-(l-ethylpyrrolidin-3-yl)-2,2- diphenyiacetonitrile.
  • the hydrolyzing comprises treatments with, sulfuric acid solution and hydrobromic acid solution.
  • (R)-2 ⁇ (l ⁇ ethylpyrrolidin ⁇ 3-yl)-2,2-diphenylacetonitrile is prepared by reacting (R)-3-chloro-l-ethylpyrfolidine with an anion of diphenylacetonitrile.
  • (R)-3-chloro-l-ethy3pyrrolidine is prepared by chlorinating (S)- l -ethylpyrroiidin-3-ol.
  • the chlorinating comprises treating (S)-l-ethylpyrrolidin-3-ol with thionyl chloride.
  • (S)- 1 -ethylpyrrolidin-3-o] is prepared by reducing (S)- 1 -acetylpyrrolidin-3-yl acetate.
  • (S)-l-acetylpyrro1idin-3-yl acetate is prepared by aeetyiating (S)-3-hydroxypyrrolidine.
  • (R)-l -ethylpyrrolidin-3-ol may be converted to a tosylate, mesylate or other nucleophilically labile hydroxy! derivative known in the art, and alkylated with the anion of diphenylacetonitrile to afford, by inversion of configuration, (R)-2-(l -ethylpyrrolidin-3-yl)-2,2-diphenylacetonitrile.
  • This compound may be further derivatized to yield (+)-ketodoxapram as described above.
  • ketodoxapram enantiomer may be obtained using the same procedures outlined herein, utilizing (R)-3-hydroxypyrrolidine, (S)- l- ethylpyrrolidin-3-ol or (S)-3-chloro-l-ethylpyrfolidine as starting materials.
  • the compounds described herein may form salts with acids, and such salts are included in the present invention.
  • the salts are pharmaceutically acceptable salts.
  • salts embraces addition salts of free acids that are useful within the methods of the invention.
  • pharmaceutically acceptable salt refers to salts that possess toxicity profiles within a range that affords utility in pharmaceutical applications. Pharmaceutically unacceptable salts may nonetheless possess properties such as high crystallinifcy, which have utility in the practice of the present invention, such as for example utility in process of synthesis, purification or composition of compounds useful within the methods of the invention.
  • Suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid.
  • inorganic acids include hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, and phosphoric acids.
  • Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, dibenzoyltartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoie, phenyiaeetic, mandelic, embonic (pamoic), methanesulfonic, ethanesuifonic, benzenesulfonic,
  • the present invention relates to the unexpected discovery that the (+)-enantiomer of ketodoxapram or a solvate thereof displays most or all the desired beneficial pharmacological activity associated with the ventilatory stimulant effects, and positive effects on arterial blood gases, of racemic ketodoxapram.
  • the present invention relates to the unexpected discovery that the (— )-enantiomer of ketodoxapram or a solvate thereof is essentially devoid of activity as a ventilator ⁇ ' or respiratory stimulant, but unexpectedly produces adverse side effects, such as hunching posture, increased urination and defecation, clonic movements and other seizure-like behaviors, pronounced drops in mean arterial blood pressure, production of cardiac arrhythmias and death.
  • compositions comprising ( + j-keodoxapram or a solvate thereof, wherein the composition is essentially free of (-— )-ketodoxapram or a solvate thereof, may be administered to a subject who is prone to or suffers from a breathing control disorder or disease in order to prevent, treat or mitigate the breathing control disorder.
  • Admi istration of a composition comprising (+)-ketodoxapram or a solvate thereof, wherein the composition is essentially free of (—-)-ketodoxapram or a solvate thereof, is unexpectedly advantageous over administration of racemic ketodoxapram or a solvate thereof because ( +j-ketodoxapram or a solvate thereof has most or all the desired beneficial pharmacological respiratory stimulant activity, together with positive effects on arterial blood gases, associated with racemic ketodoxapram but with significantly reduced adverse side effects compared to administration of racemic ketodoxapram or a solvate thereof.
  • a composition comprising (+)-ketodoxapram or a solvate thereof, wherein the composition is essentially free of ( ⁇ — )-ketodoxapram or a solvate thereof, is useful within the methods of the invention.
  • the present invention includes a method of preventing or treating a breathing control disorder or disease in a subject in need thereof.
  • the method includes administering to the subject an effective amount of a pharmaceutical composition comprising (+)-ketodoxapram or a solvate thereof and a pharmaceutically acceptable carrier, wherein the composition is essentially tree of (— -)-ketodoxapram or a solvate thereof.
  • the enantiomeric purity of the (+)-ketodoxapram or a solvate thereof is at least about 90%. In another embodiment, the enantiomeric purity of the (-H)-ketodoxapram or a solvate thereof is at least about 95%. in yet another embodiment, the enantiomeric purity of the (+)-ketodoxapram or a solvate thereof is at least about 97%. In yet another embodiment, the enantiomeric purity of the (H-)-ketodoxapram or a solvate thereof is at least about 99%. In yet another embodiment, the enantiomeric purity of the (+)-ketodoxapram or a solvate thereof is at least about 99.5%.
  • the enantiomeric purity of the (+)-ketodoxapram or a solvate thereof is at least about 99.9%. In yet another embodiment, the enantiomeric purity of the (-t-)-ketodoxapram or a solvate thereof is at least about 99.95%. In yet another embodiment, the enantiomeric purity of the (+)-ketodoxapram or a solvate thereof is at least about 99.99%.
  • the breathing control disorder or disease is selected from the group consisting of narcotic-induced respiratory depression, sleep apnea, apnea of prematurity, obesiiy-hypoventilation syndrome, primary alveolar hypoventilation syndrome, dyspnea, altitude sickness, hypoxia, hypercapnia and chronic obstructive pulmonary disease (CGPD).
  • the subject is further administered at least one additional compound useful for treating the breathing control disorder or disease.
  • the at least one additional compound is selected from the group consisting of an opioids, sedative (such as midazolam), anesthetic (such as propofol or a barbiturate), acetazolamide, almitrine, theophylline, caffeine, mefchylprogesterone and related compounds, a serotinergic modulator, a cannabinoid (such as dronabinol), and an ampakine.
  • the composition is administered to the subject in conjunction with the use of a mechanical ventilation device or positive airway pressure device.
  • the subject is a human.
  • the composition is administered to the subject by an inhalational, topical, oral, rectal, vaginal, intramuscular, subcutaneous, transdermal, intrathecal or intravenous route.
  • the present invention includes a method of preventing destabilization of or stabilizing breathing rhythm in a subject in need thereof.
  • the method includes administering to the subject an effective amount of a pharmaceutical composition comprising (+)-ketodoxapram or a solvate thereof and a pharmaceutically acceptable carrier, wherein the composition is essentially tree of (— -)-ketodoxapram or a solvate thereof.
  • the enantiomeric purity of die (+)-ketodoxapram or a solvate thereof is at least about 90%. In another embodiment, the enantiomeric purity of the (-H)-ketodoxapram or a solvate thereof is at least about 95%. in yet another embodiment, the enantiomeric purity of the (+)-ketodoxapram or a solvate thereof is at least about 97%. In yet another embodiment, the enantiomeric purity of the (H-)-ketodoxapram or a solvate thereof is at least about 99%. In yet another embodiment, the enantiomeric purity of the ( f)-ketodoxapram or a solvate thereof is a t least about 99.5%.
  • the enantiomeric purity of the (+)-ketodoxapram or a solvate thereof is at least about 99.9%. In yet another embodiment, the enantiomeric purity of the (-t-)-ketodoxapram or a solvate thereof is at least about 99.95%. In yet another embodiment, the enantiomeric purity of the (+)-ketodoxapram or a solvate thereof is at least about 99.99%.
  • the subject is further administered at least one additional compound useful for preventing destabilization of or stabilizing the breathing rhythm.
  • the at least one additional compound is selected from the group consisting of an opioids, sedative (such as midazolam), anesthetics (such as propofoi or a barbiturate ⁇ , acetazolamide, almitrine, theophylline, caffeine, methylprogesterone and related compounds, a serotonergic modulator and an ampakine.
  • the composition is administered to the subject in conjunction with the use of a mechanical ventilation device or positive airway pressure device.
  • the subject is a mammal including but not limited to a human, mouse, rat, ferret, guinea, pig, monkey, dog, cat, horse, cow, pig and other farm animals.
  • the subject is a human.
  • the composition is administered to the subject by an inhalational, topical, oral, rectal, vaginal, intramuscular, subcutaneous, transdermal, intrathecal or intravenous route.
  • the compound (+)-ketodoxapram or a solvate thereof is useful in the methods of present invention in combination with at least one additional compound useful for treating breathing control disorders or diseases.
  • additional compounds may comprise compounds of the present invention or compounds, e.g., commercially available compounds, known to treat, prevent, or reduce the symptoms of breathing control disorders.
  • the combination of the compound (+)-ketodoxapram or a solvate thereof and at least one additional compound useful for treating breathing control disorders has additive. complementary or synergistic effects in the treatment of disordered breathing, and in the treatment of sleep-related breathing control disorders.
  • the compound (+)-ketodoxapram or a solvate thereof ma be used in combination with one or more of the following drugs: an opioid, sedative (such as midazolam), anesthetics (such as propofol or barbiturate), acetazolamide, almirrine, theophylline, caffeine, methylprogesterone and related compounds, serotinergic modulator, cannabinoid (such as dronabinol) and compounds known as ampakines.
  • an opioid such as midazolam
  • anesthetics such as propofol or barbiturate
  • acetazolamide almirrine
  • theophylline caffeine
  • methylprogesterone and related compounds such as caffeine
  • serotinergic modulator such as dronabinol
  • cannabinoid such as dronabinol
  • ampakines such as dronabinol
  • Non-limiting examples of ampakines are the pyrrolidine derivative racetam drugs such as piracetara and aniracetam; the "CX-" series of drugs which encompass a range of benzoylpiperidine and benzoylpyrrolidine structures, such as CX-516 (6-(piperidin-l-yl-carbonyl)quinoxaline), CX-546 (2,3-dihydro-l,4- benzodioxin-7-yl-(l -piperidyl)methanone), CX-614 (2H,3H,6aH-pyrrolidino(2, 1 - 3',2 1 ,3-oxazino-(6',5'-5,4)benzo(e) 1 ,4-dioxan- 10-one), CX-691 (2, 1 ,3- benzoxadiazol-6-yl-piperidin- 1 -yl-rnethanone), CX-717, CX-701, CX-1739, CX- 1763
  • biarylpropylsulfonamides such as LY-392,098, LY-404, 187 (N-[2-(4*-cyanobipheny1- 4 ⁇ yl)propyl]propane-2 -sulfonamide), LY-451,646 and LY-5Q3.430 (4'- ⁇ (IS)-l-fiuoro- 2-[(isopropylsulfonyl)amino]- i -methylethy! ⁇ -N-methylbiphenyl-4-carboxamide).
  • a synergistic effect may be calculated, for example, using suitable methods such as, for example, the Sigmoid-E Python ;ax equation (Holford & Scheiner,
  • the invention also encompasses the use of pharmaceutical compositions of the compound (+)-ketodoxapram or a solvate thereof to practice the methods of the invention, wherein the compositions are essentially free of (— )- ketodoxapram or a solvate thereof.
  • Such a pharmaceutical composition may consist of the compound (+) -ketodoxapram or a solvate thereof alone, wherein the compositions is essentially free of (— -)-ketodoxapram or a solvate thereof, in a form suitable for administration to a subject, or the pharmaceutical composition may comprise the compound (+)- ketodoxapram or a solvate thereof, wherein the compositions is essentially free of (— ketodoxapram or a solvate thereof, and one or more pharmaceutically acceptable carriers, one or more additional ingredients, or some combination of these.
  • the compound ( +j-ketodoxapram may be present in the pharmaceutical composition in the form of a physiologically acceptable solvate, such as in combination with a physiologically acceptable solvent, as is well known in the art.
  • the pharmaceutical compositions useful for practicing the method of the invention may be administered to deliver a dose of between 1 ng/kg/day and 100 mg/kg/day. In another embodiment, the pharmaceutical compositions useful for practicing the invention may be administered to deliver a dose of between 1 ng/kg/day and 500 mg/kg/day.
  • compositions of the invention will van', depending upon the identity, size, and condition of the subject treated and further depending upon the route by which the composition is to be administered.
  • the composition may comprise between 0.1% and 100% (w/w) active ingredient.
  • compositions that are useful in the methods of the invention may be suitably developed for inhalational, oral, rectal, vaginal, parenteral, topical, transdermal, pulmonary, intranasal, buccal, ophthalmic, intrathecal, intravenous or another route of administration.
  • a composition useful within the methods of the invention may be directly administered to the brain, the brainstem, or any other part of the central nervous system of a mammal.
  • Other contemplated formulations include projected nanoparticies, liposomal preparations, and
  • immunologically-based formulations The route(s) of administration will be readily apparent to the skilled artisan and will depend upon any number of factors including the type and severity of the disease being treated, the type and age of the veterinary or human patient being treated, and the like.
  • compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology.
  • preparatory methods include the step of bringing the active ingredient into association with a carrier or one or more other accessory ingredients, and then, if necessary or desirable, shaping or packaging the product into a desired single- or multi-dose unit.
  • a "unit dose" is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient.
  • the amount of the active ingredient is generally equal to the dosage of the active ingredient that would be administered to a subject or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.
  • the unit dosage form may be for a single daily dose or one of multiple daily doses (e.g., about 1 to 4 or more times per day). When multiple daily doses are used, the unit dosage form may be the same or different for each dose.
  • compositions are principally directed to pharmaceutical compositions which are suitable for ethical administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts.
  • compositions suitable for administration to humans in order to render the compositions suitable for admi istration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and perform such modification with merely ordinary, if any, experimentation.
  • Subjects to which administration of the pharmaceutical compositions of the in vention is contemplated include, but are not limited to, humans and other primates, mammals including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and dogs.
  • compositions of the invention are formulated using one or more pharmaceutically acceptable excipients or carriers.
  • pharmaceutical compositions of the invention comprise a therapeutically effective amount of a compound of the invention and a
  • Pharmaceutically acceptable carriers include, but are not limited to, glycerol, water, saline, ethanoi and other pharmaceutically acceptable salt solutions such as phosphates and salts of organic acids. Examples of these and other pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1991, Mack Publication Co., New Jersey).
  • the carrier may be a solvent or dispersion medium containing, for example, water, ethanoi, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, sodium chloride, or poiyalcohols such as mannitoi and sorbitol
  • Prolonged absorption of the injectable compositions may be brought about by including in the composition an agent which delays absoiption, for example, aluminum monostearate or gelatin.
  • the pharmaceutically acceptable carrier is not DMSO alone.
  • Formulations may be employed in admixtures with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for oral, parenteral, nasal, intravenous, subcutaneous, enteral, or any other suitable mode of administration, known to the art.
  • excipients i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for oral, parenteral, nasal, intravenous, subcutaneous, enteral, or any other suitable mode of administration, known to the art.
  • the pharmaceutical preparations may be sterilized and if desired mixed with auxiliary agents, e.g., lubricants,
  • preservatives e.g., benzyl alcohol, benzyl alcohol, benzyl ether, benzyl ether, benzyl ether, benzyl ether, benzyl ether, benzyl ether sulfonylurea, benzyl ether sulfonylurea, benzyl ether sulfonylurea, benzyl ether sulfate, acetyl, acetyl sulfate, benzyl sulfate, benzyl sulfate, benzyl sulfate, benzyl sulfate, benzyl sulfonylurea, benzylurea sulfonylurea sulfonylurea sulfonylurea sulfonylurea sulfonylurea sulfonylurea sulfon
  • additional ingredients include, but are not limited to, one or more of the following: excipients; surface active agents; dispersing agents; inert diluents; granulating and disintegrating agents; binding agents; lubricating agents; sweetening agents; flavoring agents; coloring agents; preservatives;
  • physiologically degradable compositions such as gelatin; aqueous vehicles and solvents; oily vehicles and solvents; suspending agents; dispersing or wetting agents; emulsifying agents, demulcents; buffers; salts; thickening agents; fillers; emulsifying agents; antioxidants; antibiotics; antifungal agents; stabilizing agents; and
  • compositions of the invention are known in the art and described, for example in Genaro, ed. (1985, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA), which is incorporated herein by reference.
  • composition of the in vention may comprise a preservati ve from about 0.005% to 2.0% by total weight of the composition.
  • the preservative is used to prevent spoilage in the case of exposure to contaminants in the environment.
  • preservatives useful in accordance with the invention included but are not limited to those selected from the group consisting of benzyl alcohol, sorbic acid, parabens, imidurea and combinations thereof.
  • a particularly preferred preservative is a combination of about 0.5% to 2.0% benzyl alcohol and 0.05% to 0.5% sorbic acid.
  • the composition preferably includes an antioxidant and a chelating agent which inhibit the degradation of the compound.
  • Preferred antioxidants for some compounds are BHT, BHA, aipha-tocopherol and ascorbic acid in the preferred range of about 0.01 % to 0.3% and more preferably BHT in the range of 0.03% to 0.1 % by weight by total weight of the composition.
  • the chelating agent is present in an amount of from 0.01% to 0.5% by weight by total weight of the composition.
  • Particularly preferred chelating agents include edetate salts (e.g. disodium edetate) and citric acid in the weight range of about 0.01% to 0.20% and more preferably in the range of 0.02% to 0.10% by weight by total weight of the composition.
  • the chelating agent is useful for chelating metal ions in the composition which may be detrimental to the shelf life of the formulation. While BHT and disodium edetate are the particularly preferred antioxidant and chelating agent respectively for some compounds, other suitable and equivalent antioxidants and chelating agents may be substituted therefore as would be known to those skilled in the art.
  • Liquid suspensions may be prepared using conventional methods to achieve suspension of the active ingredient in an aqueous or oily vehicle.
  • Aqueous vehicles include, for example, water, and isotonic saline.
  • Oily vehicles include, for example, almond oil, oily esters, ethyl alcohol, vegetable oils such as arachis, olive, sesame, or coconut oil, fractionated vegetable oils, and mineral oils such as liquid paraffin.
  • Liquid suspensions may further comprise one or more additional ingredients including, but not limited to, suspending agents, dispersing or wetting agents, emulsifying agents, demulcents, preservatives, buffers, salts, flavorings, coloring agents, and sweetening agents.
  • Oily suspensions may further comprise a thickening agent.
  • suspending agents include, but are not limited to, sorbitol syrup, hydrogenated edible fats, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, and cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose.
  • Known dispersing or wetting agents include, but are not limited to, naturally-occurring phosphatides such as lecithin, condensation products of an alkylene oxide with a fatty acid, with a long chain aliphatic alcohol, with a partial ester derived from a fatty acid and a hexitol, or with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene stearate, heptadecaethyleneoxycetanoi, polyoxyethylene sorbitol monooieate, and polyoxyethylene sorbitan monooieate, respectively).
  • Known emulsifying agents include, but are not limited to, lecithin, and acacia.
  • Known preservatives include, but are not limited to, methyl, ethyl, or n-propyl para- hydroxybenzoates, ascorbic acid, and sorbic acid.
  • Known sweetening agents include, for example, glycerol, propylene glycol, sorbitol, sucrose, and saccharin.
  • Known thickening agents for oily suspensions include, for example, beeswax, hard paraffin, and cetyl alcohol.
  • Liquid solutions of the active ingredient in aqueous or oily solvents may be prepared in substantially the same manner as liquid suspensions, the primary difference being that the active ingredient is dissolved, rather than suspended in the solvent.
  • an "oily" liquid is one which comprises a carbon-containing liquid molecule and which exhibits a less polar character than water.
  • Liquid solutions of the pharmaceutical composition of the invention may comprise each of the components described with regard to liquid suspensions, it being understood that suspending agents will not necessarily aid dissolution of the active ingredient in the solvent.
  • Aqueous solvents include, for example, water, and isotonic saline.
  • Oily solvents include, for example, almond oil, oily esters, ethyl alcohol, vegetable oils such as arachis, olive, sesame, or coconut oil, tractionated vegetable oils, and mineral oils such as liquid paraffin.
  • Powdered and granular formulations of a pharmaceutical preparation of the invention may be prepared using known methods. Such formulations may be administered directly to a subject, used, for example, to form tablets, to fill capsules, or to prepare an aqueous or oily suspension or solution by addition of an aqueous or oily vehicle thereto. Each of these formulations may further comprise one or more of dispersing or wetting agent, a suspending agent, and a preservative. Additional excipients, such as fillers and sweetening, flavoring, or coloring agents, may also be included in these formulations.
  • a pharmaceutical composition of the invention may also be prepared, packaged, or sold in the form of oil-in-water emulsion or a water-in-oil emulsion.
  • the oily phase may be a vegetable oil such as olive or arachis oil, a mineral oil such as liquid paraffin, or a combination of these.
  • compositions may further comprise one or more emulsifying agents such as naturally occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soybean or lecithin phosphatide, esters or partial esters derived from combinations of fatty acids and hexitol anhydrides such as sorbitan monooleate, and condensation products of such partial esters with ethylene oxide such as poiyoxyethylene sorbitan monooleate.
  • emulsions may also contain additional ingredients including, for example, sweetening or flavoring agents.
  • Methods for impregnating or coating a material with a chemical composition include, but are not limited to methods of depositing or binding a chemical composition onto a surface, methods of
  • incorporating a chemical composition into the structure of a material during the synthesis of the material i.e., such as with a physiologically degradable material
  • methods of absorbing an aqueous or oily solution or suspension into an absorbent material with or without subsequent drying.
  • the regimen of administration may affect what constitutes an effective amount.
  • the therapeutic formulations may be administered to the patient either prior to or after the onset of a breathing control disorder event. Further, several divided dosages, as well as staggered dosages may be administered daily or sequentially, or the dose may be continuously infused, or may be a bolus injection. Further, the dosages of the therapeutic formulations may be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophy lactic situation.
  • compositions of the present invention may be carried out using known procedures, at dosages and for periods of time effective to treat a breathing control disorder or disease in the patient.
  • An effective amount of the therapeutic compound necessary to achieve a therapeutic effect may vary according to factors such as the activity of the particular compound employed; the time of administration; the rate of excretion of the compound; the duration of the treatment; other drugs, compounds or materials used in combination with the compound; the state of the disease or disorder, age, sex. weight, condition, general health and prior medical history of the patient being treated, and like factors well-known in the medical arts. Dosage regimens may be adjusted to provide the optimum therapeutic response.
  • an effective dose range for a therapeutic compound of the invention is from about 0.01 and 50 nig/kg of body weight/per day.
  • One of ordinary skill in the art would be able to study the relevant factors and make the determination regarding the effective amount of the therapeutic compound without undue experimentation.
  • the compound can be administered to an animal as frequently as several times daily, or it may be administered less frequently, such as once a day, once a week, once every two weeks, once a month, or even less frequently, such as once every several months or even once a year or less.
  • the amount of compound dosed per day may be administered , in non-limiting examples, every day, every other day, every 2 days, every 3 days, every 4 days, or every 5 days.
  • a 5 mg per day dose may be initiated on Monday with a first subsequent 5 mg per day dose administered on Wednesday, a second subsequent 5 mg per day dose administered on Friday, and so on.
  • the frequency of the dose will be readily apparent to the skilled artisan and will depend upon any number of factors, such as, but not limited to, the type and severity of the disease being treated, the type and age of the animal, etc.
  • Actual dosage levels of the acti ve ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • a medical doctor e.g., physician or veterinarian, having ordinary skill in the art may readily determine and prescribe the effective amount of the
  • the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the patients to be treated; each unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceuticai vehicle.
  • the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding/formulating such a therapeutic compound for the treatment of breathing control disorders in a patient.
  • compositions of the invention are administered to the patient in dosages that range from one to five times per day or more.
  • compositions of the in vention are administered to the patient in range of dosages that include, but are not limited to, once every day, every two, days, every three days to once a week, and once every two weeks.
  • the frequency of administration of the various combination compositions of the invention will vary from subject to subject depending on many factors including, but not limited to, age, disease or disorder to be treated, gender, overall health, and other factors.
  • the invention should not be construed to be limited to any particular dosage regime and the precise dosage and composition to be administered to any patient will be determined by the attending physical taking all other factors about the patient into account.
  • Compounds of the invention for administration may be in the range of from about 1 , ug to about 7,500 mg, about 20 ⁇ g to about 7,000 mg, about 40 ,ug to about 6,500 mg, about 80 fig to about 6,000 mg, about 100 g to about 5,500 mg, about 200 .g to about 5,000 mg, about 400 ,ug to about 4,000 mg, about 800 ⁇ ig to about 3,000 mg, about 1 mg to about 2,500 mg, about 2 mg to about 2,000 mg, about 5 mg to about 1 ,000 mg, about 10 mg to about 750 mg, about 20 mg to about 600 mg, about 30 mg to about 500 mg, about 40 mg to about 400 mg, about 50 mg to about 300 mg, about 60 mg to about 250 mg, about 70 mg to about 200 mg, about 80 mg to about 150 mg, and any and all whole or partial increments therebetween.
  • the dose of a compound of the invention is from about 0.5 ig and about 5,000 mg. In some embodiments, a dose of a compound of the invention used in compositions described herein is less than about 5,000 mg, or less than about 4,000 mg, or less than about 3,000 mg, or less than about 2,000 mg, or less than about 1 ,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 200 mg, or less than about 50 mg.
  • a dose of a second compound as described herein is less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 400 mg, or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 40 mg, or less than about 30 mg, or less than about 25 mg, or less than about 20 mg, or less than about 15 mg, or less than about 10 mg, or less than about 5 mg, or less than about 2 mg, or less than about 1 mg, or less than about 0.5 mg, and any and all whole or partial increments thereof.
  • the present invention is directed to a packaged pharmaceutical composition
  • a packaged pharmaceutical composition comprising a container holding a therapeutically effective amount of a compound of the invention, alone or in combination with a second pharmaceutical agent; and instructions for using the compound to treat, prevent, or reduce one or more symptoms of breathing control disorder in a patient.
  • the term "container” includes any receptacle for holding the pharmaceutical composition.
  • the container is the packaging that contains the pharmaceutical composition.
  • the container is not the packaging that contains the pharmaceutical composition, i.e., the container is a receptacle, such as a box or vial that contains the packaged
  • the instructions for use of the pharmaceutical composition may be contained on the packaging containing the pharmaceutical composition, and as such the instructions form an increased functional relationship to the packaged product.
  • the instructions may contain information pertaining to the compound's ability to perform its intended function, e.g., treating, preventing, or reducing a breathing control disorder in a patient.
  • Routes of administration of any of the compositions of the invention include inhalational, oral, nasal, rectal, parenteral, sublingual, transdermal, transmucosal (e.g., sublingual, lingual, (trans)buccal, ( transurethral, vaginal (e.g., trans- and perivaginal! ⁇ '), (intranasal, and (transrectal, intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.
  • compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration and the like. It should be understood that the formulations and compositions that would be useful in the present invention are not limited to the particular formulations and compositions that are described herein.
  • compositions suitable for oral administration include, but are not limited to, a powdered or granular
  • compositions intended for oral use may be prepared according to any method known in the art and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharrnaceuticaliy excipients which are suitable for the manufacture of tablets.
  • excipients include, for example an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate.
  • Tablets may be non-coated or they may be coated using known methods to achieve delayed disintegration in the gastrointestinal tract of a subject, thereby providing sustained release and absorption of the active ingredient.
  • a material such as glyceryl monostearate or glyceryl distearate may be used to coat tablets.
  • tablets may be coated using methods described in U.S. Patents Nos. 4,256, 108; 4,160,452; and 4,265,874 to form osmotical!y controlled release tablets.
  • Tablets may further comprise a sweetening agent, a flavoring agent, a coloring agent, a preservative, or some combination of these in order to provide for pharmaceutically elegant and palatable preparation.
  • Hard capsules comprising the active ingredient may be made using a physiologically degradable composition, such as gelatin. Such hard capsules comprise the active ingredient, and may further comprise additional ingredients including, for example, an inert solid diluent such as calcium carbonate, calcium phosphate, or kaolin.
  • an inert solid diluent such as calcium carbonate, calcium phosphate, or kaolin.
  • Soft gelatin capsules comprising the active ingredient may be made using a physiologically degradable composition, such as gelatin.
  • Such soft capsules comprise the active ingredient, which may be mixed with water or an oil medium such as peanut oil, liquid paraffin, or olive oil.
  • the compounds of the invention may be in the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents; fillers; lubricants; disintegrates; or wetting agents.
  • the tablets may be coated using suitable methods and coating materials such as OPADRYTM film coating systems available from Coiorcon, West Point, Pa. (e.g., OPADRYTM OY Type, OYC Type, Organic Enteric OY-P Type, Aqueous Enteric ⁇ - ⁇ Type, OY-PM Type and OPADRYTM White,
  • Liquid preparation for oral administration may be in the form of solutions, syrups or suspensions.
  • the liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agent (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl para-hydroxy benzoates or sorbic acid).
  • suspending agents e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats
  • emulsifying agent e.g., lecithin or acacia
  • non-aqueous vehicles e.g., almond oil, oily esters or ethyl alcohol
  • preservatives e.g., methyl or propyl para-hydroxy benzoates or sorbic acid
  • a tablet comprising the active ingredient may, for example, be made by compressing or molding the active ingredient, optionally with one or more additional ingredients.
  • Compressed tablets may be prepared by compressing, in a suitable device, the active ingredient in a free-flowing form such as a powder or granular preparation, optionally mixed with one or more of a binder, a lubricant, an excipient, a surface active agent, and a dispersing agent.
  • Molded tablets may be made by molding, in a suitable device, a mixture of the active ingredient, a
  • Pharmaceutically acceptable excipients used in the manufacture of tablets include, but are not limited to, inert diluents, granulating and disintegrating agents, binding agents, and lubricating agents.
  • Known dispersing agents include, but are not limited to, potato starch and sodium starch glycollate.
  • Known surface-active agents include, but are not limited to, sodium lauryi sulphate.
  • Known diluents include, but are not limited to, calcium carbonate, sodium carbonate, lactose, microcrystalline cellulose, calcium phosphate, calcium hydrogen phosphate, and sodium phosphate.
  • Known granulating and disintegrating agents include, but are not limited to, corn starch and alginic acid.
  • Known binding agents include, but are not limited to, gelatin, acacia, pre -gelatinized maize starch, polyvinylpyrrolidone, and hydroxypropyl methylcellulose.
  • Known lubricating agents include, but are not limited to, magnesium stearate, stearic acid, silica, and talc.
  • Granulating techniques are well known in the pharmaceutical art for modifying starting powders or other particulate materials of an active ingredient.
  • the powders are typically mixed with a binder material into larger permanent free-flowing agglomerates or granules referred to as a "granulation.”
  • solvent-using "wet" granulation processes are generally characterized in that the powders are combined with a binder material and moistened with water or an organic solvent under conditions resulting in the formation of a wet granulated mass from which the solvent must then be evaporated.
  • Melt granulation generally consists in the use of materials that are solid or semi-solid at room temperature (i.e. having a relatively low softening or melting point range) to promote granulation of powdered or other materials, essentially in the absence of added water or other liquid solvents.
  • the low melting solids when heated to a temperature in the melting point range, liquefy to act as a binder or granulating medium.
  • the liquefied solid spreads itself over the surface of powdered materials with which it is contacted, and on cooling, forms a solid granulated mass in which the initial materials are bound together.
  • the resulting melt granulation may then be provided to a tablet press or be encapsulated for preparing the oral dosage form.
  • Melt granulation improves the dissolution rate and bioavailability of an active (i.e. drug) by forming a solid dispersion or solid solution.
  • U.S. Patent No. 5, 169,645 discloses directly compressible wax- containing granules having improved flo properties.
  • the granules are obtained when waxes are admixed in the melt with certain flow improving additives, followed by cooling and granulation of the admixture.
  • certain flow improving additives such as sodium bicarbonate
  • both the wax(es) and the additives(s) will melt.
  • the present invention also includes a multi-layer tablet comprising a layer providing for the delayed release of one or more compounds useful within the methods of the invention, and a further layer providing for the immediate release of one or more compounds useful within the methods of the invention.
  • a gastric insoluble composition may be obtained in which the active ingredient is entrapped, ensuring its delayed release.
  • Parenteral administration thus includes, but is not limited to, administration of a pharmaceutical composition by injection of the composition, by application of the composition through a surgical incision, by application of the composition through a tissue-penetrating non-surgical wound, and the like.
  • parenteral administration is contemplated to include, but is not limited to, subcutaneous, intravenous (single dose or infusion), intraperitoneal, intramuscular, intrasternal injection, and kidney dialytic infusion techniques.
  • Formulations of a pharmaceutical composition suitable for parenteral administration comprise the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampules or in multi-dose containers containing a preservative. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents.
  • the active ingredient is provided in dry (i.e., powder or granular) form for reconstitution with a suitable vehicle (e.g., sterile pyrogen-free water) prior to parenteral administration of the reconstituted composition.
  • a suitable vehicle e.g., sterile pyrogen-free water
  • compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution.
  • This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein.
  • Such sterile injectable formulations may be prepared using a non-toxic parenterally-acceptable diluent or solvent, such as water or 1 ,3-butane diol, for example.
  • Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides.
  • compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.
  • stratum coraeum layer of the epidermis An obstacle for topical administration of pharmaceuticals is the stratum coraeum layer of the epidermis.
  • the stratum corneum is a highly resistant layer comprised of protein, cholesterol, sphingolipids, free fatty acids and various other lipids, and includes cornified and living cells.
  • One of the factors that limit the penetration rate (flux) of a compound through the stratum corneum is the amount of the active substance that can be loaded or applied onto the skin surface. The greater the amount of active substance which is applied per unit of area of the skin, the greater the concentration gradient between the skin surface and the lower layers of the skin, and in turn the greater the diffusion force of the active substance through the skin. Therefore, a formulation containing a greater concentration of the active substance is more likely to result in penetration of the active substance through the skin, and more of it, and at a more consistent rate, than a formulation having a lesser concentration, all other things being equal.
  • Formulations suitable for topical administration include, but are not limited to, liquid or semi-liquid preparations such as liniments, lotions, oii-in-water or water-m-oil emulsions such as creams, ointments or pastes, and solutions or suspensions.
  • Topically administrabie formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent.
  • Formulations for topical administration may further comprise one or more of the additional ingredients described herein.
  • Enhancers of permeation may be used. These materials increase the rate of penetration of drugs across the skin. Typical enhancers in the art include ethanol, glycerol monolaurate, PGML (polyethylene glycol monolaurate), dimethylsulfoxide, and the like. Other enhancers include oleic acid, oleyl alcohol, ethoxydiglycol, laurocapram, alkanecarboxylic acids, dimethylsulfoxide, polar lipids, or N-me thy 1-2 -pyrroli d o e.
  • compositions of the invention may contain liposomes.
  • the composition of the liposomes and their use are known in the art (for example, see Constanza, U.S. Patent No. 6,323,219).
  • the topically active pharmaceutical composition may be optionally combined with other ingredients such as adjuvants, anti-oxidants, chelating agents, surfactants, foaming agents, wetting agents, emulsifying agents, viscosifiers, buffering agents, preservatives, and the like.
  • a permeation or penetration enhancer is included in the composition and is effective in improving the percutaneous penetration of the active ingredient into and through the stratum corneum with respect to a composition lacking the permeation enhancer.
  • compositions may further comprise a hydrotropic agent, which functions to increase disorder in the structure of the stratum corneum, and thus allows increased transport across the stratum corneum.
  • hydrotropic agents such as isopropyl alcohol, propylene glycol, or sodium xylene sulfonate, are known to those of skill in the art.
  • the topically active pharmaceutical composition should be applied in an amount effective to affect desired changes.
  • amount effective shall mean an amount sufficient to cover the region of skin surface where a change is desired.
  • An active compound should be present in the amount of from about 0.0001 % to about 15% by weight volume of the composition. More preferable, it should be present in an amount from about 0.0005% to about 5% of the composition; most preferably, it should be present in an amount of from about 0.001% to about 1% of the composition.
  • Such compounds may be synthetically-or naturally derived.
  • a pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for buccal administration.
  • Such formulations may, for example, be in the form of tablets or lozenges made using conventional methods, and may contain, for example, 0.1 to 20% (w/w) of the active ingredient, the balance comprising an orally dissolvable or degradable composition and, optionally, one or more of the additional ingredients described herein.
  • formulations suitable for buccal administration may comprise a powder or an aerosolized or atomized solution or suspension comprising the active ingredient.
  • Such powdered, aerosolized, or aerosolized formulations when dispersed, preferably have an average particle or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients described herein.
  • the examples of formulations described herein are not exhaustive and it is understood that the invention includes additional modifications of these and other formulations not described herein, but which are known to those of skill in the art.
  • a pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for rectal administration.
  • a composition may be in the form of, for example, a suppository, a retention enema preparation, and a solution for rectal or colonic irrigation.
  • Suppository formulations may be made by combining the active ingredient with a non-irritating pharmaceutically acceptable excipient which is solid at ordinary room temperature (i.e., about 20 C C) and which is liquid at the rectal temperature of the subject (i.e., about 37°C in a healthy human).
  • a non-irritating pharmaceutically acceptable excipient which is solid at ordinary room temperature (i.e., about 20 C C) and which is liquid at the rectal temperature of the subject (i.e., about 37°C in a healthy human).
  • pharmaceutically acceptable excipients include, but are not limited to, cocoa butter, polyethylene glycols, and various giycerides. Suppository formulations may further comprise various additional ingredients including, but not limited to, antioxidants, and preservatives.
  • Retention enema preparations or solutions for rectal or colonic irrigation may be made by combining the active ingredient with a pharmaceutically acceptable liquid carrier.
  • enema preparations may be administered using, and may be packaged within, a delivery device adapted to the rectal anatomy of the subject.
  • Enema preparations may further comprise various additional ingredients including, but not limited to, antioxidants, and preservatives.
  • Additional dosage forms of this invention include dosage forms as described in U.S. Patents Nos. 6,340,475, 6,488,962, 6,451,808, 5,972,389,
  • Additional dosage forms of this invention also include dosage forms as described in U.S. Patent Applications Nos. 20030147952,
  • Additional dosage forms of this invention also include dosage forms as described in PCT Applications Nos. WO 03/35041, WO 03/35040, WO 03/35029, WO 03/35177, WO 03/35039, WO 02/96404, WO 02/32416, WO 01/97783, WO 01 /56544, WO 01 /32217, WO 98/55107, WO 98/11879, WO 97/47285, WO 93/18755, and WO 90/1 1757.
  • Controlled- or sustained-release formulations of a pharmaceutical composition of the invention may be made using conventional technology.
  • the dosage forms to be used can be provided as slo or controlled-release of one or more active ingredients therein using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, or microspheres or a combination thereof to provide the desired release profile in varying proportions.
  • Suitable controlled-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the pharmaceutical compositions of the invention.
  • single unit dosage forms suitable for oral administration such as tablets, capsules, gelcaps and capiets, which are adapted for controlled-release are encompassed by the present invention.
  • controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts.
  • the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time.
  • Advantages of controlled-release formulations include extended activity of the drug, reduced dosage frequency, and increased patient compliance.
  • controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as blood level of the drug, and thus can affect the occurrence of side effects.
  • controlled-release formulations are designed to initially release an amount of drug that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drug to maintain this level of therapeutic effect over an extended period of time.
  • the drug In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body.
  • Controlled-release of an active ingredient can be stimulated by various inducers, for example pH, temperature, enzymes, water, or other physiological conditions or compounds.
  • controlled-release component in the context of the present invention is defined herein as a compound or compounds, including, but not limited to, polymers, polymer matrices, gels, permeable membranes, liposomes, or microspheres or a combination thereof that facilitates the controlled-release of the active ingredient.
  • the formulations of the present invention may ⁇ be, but are not limited to, short-term, rapid-offset, as well as controlled, for example, sustained release, delayed release and pulsatile release formulations.
  • sustained release is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that may, although not necessarily, result in substantially constant blood levels of a drug over an extended time period.
  • the period of time may be as long as a month or more and should be a release which is longer that the same amount of agent administered in bolus form.
  • the compounds for sustained release, may be formulated with a suitable polymer or hydrophobic material which provides sustained release properties to the compounds.
  • the compounds for use the method of the invention may be administered in the form of microparticies, for example, by injection or in the form of wafers or discs by implantation.
  • the compounds of the invention are administered to a patient, alone or in combination with another pharmaceutical agent, using a sustained release formulation.
  • delayed release is used herein in its conventional sense to refer to a drag formulation that provides for an initial release of the drug after some delay following drug administration and that may, although not necessarily, includes a delay of from about 10 minutes up to about 12 hours.
  • pulsatile release is used herein in its conventional sense to refer to a drug formulation that provides release of the drug in such a way as to produce pulsed plasma profiles of the drug after drug administration.
  • immediate release is used in its conventional sense to refer to a drag formulation that provides for release of the drag immediately after drag administration.
  • short-term refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes and any or all whole or partial increments thereof after drug administration after drug administration.
  • rapid-offset refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes, and any and all whole or partial increments thereof after drag administration.
  • a method of treating a patient lacking normal breathing comprises administering the composition useful within the invention as described herein, and additionally treating the patient using a device for treatment of a lack of normal breathing.
  • Such devices include, but are not limited to, ventilation devices, CPAP and BiPAP devices.
  • Mechanical ventilation is a method to mechanically assist or replace spontaneous breathing.
  • Mechanical ventilation is typically used after an invasive intubation, a procedure wherein an endotracheal or tracheostomy tube is inserted into the airway. It is normally used in acute settings, such as in the ICU, for a short period of time during a serious illness. It may also be used at home or in a nursing or rehabilitation institution, if patients have chronic illnesses that require long-term ventilation assistance.
  • the main form of mechanical ventilation is positive pressure ventilation, which works by increasing the pressure in the patient's airway and thus forcing air into the lungs.
  • Negative lung for example, the "iron lung”
  • Mechanical ventilation is often a life- saving intervention, but carries many potential complications including
  • Types of mechanical ventilation are: conventional ventilation, high frequency ventilation, non-invasive ventilation (non-invasive positive pressure pentilation or NIPPV), proportional assist ventilation (PAV), adaptive support ventilation (ASV) and neurally adjusted ventilatory assist (NAVA).
  • NIPPV non-invasive positive pressure pentilation
  • PAV proportional assist ventilation
  • ASV adaptive support ventilation
  • NAVA neurally adjusted ventilatory assist
  • Non-invasive ventilation refers to all modalities that assist ventilation without the use of an endotracheal tube.
  • Non-invasive ventilation is primarily aimed at minimizing patient discomfort and the complications associated with invasive ventilation, and is often used in cardiac disease, exacerbations of chronic pulmonary- disease, sleep apnea, and neuromuscular diseases.
  • Non-invasive ventilation refers only to the patient interface and not the mode of ventilation used; modes may include spontaneous or control modes and may be either pressure or volume modes.
  • Some commonly used modes of NIPPV include:
  • CPAP Continuous positive airway pressure
  • BIPAP Bi-level positive airway pressure
  • reaction conditions including but not limited to reaction times, reaction size/volume, and experimental reagents, such as solvents, catalysts, pressures, atmospheric conditions, e.g., nitrogen atmosphere, and reducing/oxidizing agents, with art-recognized alternatives and using no more than routine experimentation, are within the scope of the present application.
  • range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
  • Example 1 Unless otherwise noted, all remaining starting materials were obtained from commercial suppliers and used without purification.
  • Example 1 Example 1 :
  • the operating conditions used for the separation process are as follows.
  • the column was C ' f U RALPAK AD (5 urn, 4.6 mm ID x 250 mm).
  • the mobile phase was EtOH with 0.1 % TEA (triethylamine).
  • the flow rate was 1 mL/min at 30 °C.
  • the temperature of the column was kept at room temperature, and LJV detection was performed at 230 nm.
  • a solution of racemic ketodoxapram (2.3 g) was injected onto the chromatographic column using the conditions illustrated above.
  • the appropriate fractions collected from the chromatographic process were concentrated to dryness. After solvent removal, the products were dried to obtain two fractions: the first eluent, in a total of 0.974 g, with a recovery yield of 84.7% and an enantiomeric excess of 99.9%; the second eluent, in a total of 0.0995 g, with a recovery yield of 86.5% and an enantiomeric excess of 98.2%.
  • the (-i-)-enantiomer of 4-[2-( 1 -ethy3-5-Qxo-4,4-diphenyl-pyrroiidin-3- yl)-ethy]]-morpholin-3-one (19) was prepared from the (+)-enantiomer of l-eihyl-4- (2 ⁇ iodo-ethyl) ⁇ 3,3-diphenylpyrrolidin-2-one (18), morpholin-3-one, sodium hydride in DMF, as described in Example 1.
  • tracheal airflow was recorded for 20-30 minutes prior to compound administration.
  • Vehicle and test compound were administered intravenously over 15-25 seconds and at a constant volume (1 mL/kg). At least 15- min elapsed between each dose of compound administered.
  • Tracheal airflow was recorded continuously before, during and after compound administration.
  • Tidal volume was derived from the integral of airflow and respiratory rate was derived from the number of inspirator ⁇ ' ' cycles per minute. Minute volume was calculated as the product of tidal volume and respiratory rate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé de traitement d'une maladie ou d'un trouble de la régulation de la respiration chez un sujet qui en a besoin, ledit procédé comportant l'administration au sujet d'une quantité thérapeutiquement efficace d'une composition pharmaceutique comportant du (+)-kétodoxapram ou un solvate de celui-ci et un support de qualité pharmaceutique, la composition étant essentiellement exempte de (-)-kétodoxapram ou d'un solvate de celui-ci.
PCT/US2012/040195 2011-06-03 2012-05-31 Compositions et procédés pour traitement des troubles ou maladies de la régulation de la respiration WO2012166909A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161492988P 2011-06-03 2011-06-03
US61/492,988 2011-06-03

Publications (1)

Publication Number Publication Date
WO2012166909A1 true WO2012166909A1 (fr) 2012-12-06

Family

ID=47259849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/040195 WO2012166909A1 (fr) 2011-06-03 2012-05-31 Compositions et procédés pour traitement des troubles ou maladies de la régulation de la respiration

Country Status (1)

Country Link
WO (1) WO2012166909A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078575A2 (fr) * 2012-11-15 2014-05-22 Galleon Pharmaceuticals, Inc. Nouveaux composés de modulation de régulation de la respiration oralement biodisponibles et leurs procédés d'utilisation
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987237B2 (en) 2011-11-23 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10258630B2 (en) 2014-10-22 2019-04-16 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471148B2 (en) 2012-06-18 2019-11-12 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2020035541A1 (fr) 2018-08-15 2020-02-20 Universität Heidelberg Inhibiteurs task-1 pour le traitement d'arythmies auriculaires
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN118063369A (zh) * 2024-04-18 2024-05-24 成都瑞尔医药科技有限公司 一种盐酸多沙普仑的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3192221A (en) * 1961-12-04 1965-06-29 Robins Co Inc A H 4-(omega-substituted alkyl)-3, 3-disubstituted-1-substituted-2-pyrrolidinones and 4-(omega-substituted alkyl)-3, 3-disubstituted-1-substituted-2-thionpyrrolidinones and production thereof
US3318908A (en) * 1962-06-18 1967-05-09 Robins Co Inc A H 3-cyanopyrrolidines
US3576819A (en) * 1968-02-26 1971-04-27 Robins Co Inc A H Esters of alpha-(1-substituted-3-pyrrolidinyl)-alpha-phenyl acetic acid
US4002766A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated Antiarrhythmia methods
US4990683A (en) * 1986-10-27 1991-02-05 A. H. Robins Company, Incorporated Process for preparing 3-pyrrolidinols
US20100105685A1 (en) * 2006-10-03 2010-04-29 Galleon Pharmaceuticals, Inc. S-Nitrosothiol Compounds and Related Derivatives
US20120101073A1 (en) * 2010-10-22 2012-04-26 Galleon Pharmaceutical, Inc. Novel Method For Treating Breathing Disorders or Diseases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3192221A (en) * 1961-12-04 1965-06-29 Robins Co Inc A H 4-(omega-substituted alkyl)-3, 3-disubstituted-1-substituted-2-pyrrolidinones and 4-(omega-substituted alkyl)-3, 3-disubstituted-1-substituted-2-thionpyrrolidinones and production thereof
US3318908A (en) * 1962-06-18 1967-05-09 Robins Co Inc A H 3-cyanopyrrolidines
US3576819A (en) * 1968-02-26 1971-04-27 Robins Co Inc A H Esters of alpha-(1-substituted-3-pyrrolidinyl)-alpha-phenyl acetic acid
US4002766A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated Antiarrhythmia methods
US4990683A (en) * 1986-10-27 1991-02-05 A. H. Robins Company, Incorporated Process for preparing 3-pyrrolidinols
US20100105685A1 (en) * 2006-10-03 2010-04-29 Galleon Pharmaceuticals, Inc. S-Nitrosothiol Compounds and Related Derivatives
US20120101073A1 (en) * 2010-10-22 2012-04-26 Galleon Pharmaceutical, Inc. Novel Method For Treating Breathing Disorders or Diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAIRAM ET AL., PHARMACODYNAMIC EFFECTS AND PHARMACOKINETIC PROFILES OF KETO-DOXAPRAM AND DOXAPRAM IN NEWBOM LAMBS, vol. 28, 1990, pages 142 - 146 *

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248136B2 (en) 2011-11-23 2016-02-02 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9114145B2 (en) 2011-11-23 2015-08-25 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10675288B2 (en) 2011-11-23 2020-06-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11103516B2 (en) 2011-11-23 2021-08-31 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987237B2 (en) 2011-11-23 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8993549B2 (en) 2011-11-23 2015-03-31 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8993548B2 (en) 2011-11-23 2015-03-31 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11793819B2 (en) 2011-11-23 2023-10-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9114146B2 (en) 2011-11-23 2015-08-25 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11166963B2 (en) 2012-06-18 2021-11-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11865179B2 (en) 2012-06-18 2024-01-09 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US10639375B2 (en) 2012-06-18 2020-05-05 Therapeuticsmd, Inc. Progesterone formulations
US10471148B2 (en) 2012-06-18 2019-11-12 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US8987238B2 (en) 2012-06-18 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9006222B2 (en) 2012-06-18 2015-04-14 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US11529360B2 (en) 2012-06-18 2022-12-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9012434B2 (en) 2012-06-18 2015-04-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11110099B2 (en) 2012-06-18 2021-09-07 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11033626B2 (en) 2012-06-18 2021-06-15 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014078575A3 (fr) * 2012-11-15 2014-10-16 Galleon Pharmaceuticals, Inc. Nouveaux composés de modulation de régulation de la respiration oralement biodisponibles et leurs procédés d'utilisation
WO2014078575A2 (fr) * 2012-11-15 2014-05-22 Galleon Pharmaceuticals, Inc. Nouveaux composés de modulation de régulation de la respiration oralement biodisponibles et leurs procédés d'utilisation
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11622933B2 (en) 2012-12-21 2023-04-11 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11497709B2 (en) 2012-12-21 2022-11-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10835487B2 (en) 2012-12-21 2020-11-17 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10888516B2 (en) 2012-12-21 2021-01-12 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11351182B2 (en) 2012-12-21 2022-06-07 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11304959B2 (en) 2012-12-21 2022-04-19 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11065197B2 (en) 2012-12-21 2021-07-20 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11241445B2 (en) 2012-12-21 2022-02-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11123283B2 (en) 2012-12-21 2021-09-21 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11116717B2 (en) 2012-12-21 2021-09-14 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11103513B2 (en) 2014-05-22 2021-08-31 TherapeuticsMD Natural combination hormone replacement formulations and therapies
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10258630B2 (en) 2014-10-22 2019-04-16 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10668082B2 (en) 2014-10-22 2020-06-02 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10398708B2 (en) 2014-10-22 2019-09-03 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10912783B2 (en) 2015-07-23 2021-02-09 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10532059B2 (en) 2016-04-01 2020-01-14 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2020035541A1 (fr) 2018-08-15 2020-02-20 Universität Heidelberg Inhibiteurs task-1 pour le traitement d'arythmies auriculaires
US20210308103A1 (en) * 2018-08-15 2021-10-07 Universität Heidelberg Task-1 inhibitors for treatment of atrial arrhythmias
CN118063369A (zh) * 2024-04-18 2024-05-24 成都瑞尔医药科技有限公司 一种盐酸多沙普仑的制备方法

Similar Documents

Publication Publication Date Title
WO2012166909A1 (fr) Compositions et procédés pour traitement des troubles ou maladies de la régulation de la respiration
US20120101073A1 (en) Novel Method For Treating Breathing Disorders or Diseases
US20120270848A1 (en) Novel Compositions and Therapeutic Methods Using Same
US8182837B2 (en) Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
US20230414572A1 (en) Prevention or treatment of sleep disorders using dexmedetomidine formulation
CN101896205A (zh) 使用nmda拮抗剂用于获得麻醉剂节约效果的组合物和方法
US20210145785A1 (en) Compositions and methods for stimulating ventilatory and/or respiratory
KR20010032009A (ko) 수면성 무호흡의 치료에 미타자핀을 사용하는 방법
Katsanoulas et al. Undiagnosed central anticholinergic syndrome may lead to dangerous complications
CA2623184A1 (fr) Combinaison de produits pharmaceutiques a base de s-nitrosothiol pour retablir un rythme respiratoire normal
US12011428B2 (en) Compositions and methods for stimulating ventilatory and/or respiratory drive
US10543187B2 (en) Compositions and methods for stimulating ventilatory and/or respiratory drive
JP2016516714A (ja) 呼吸制御調節化合物およびそれを使用する方法
US20100105685A1 (en) S-Nitrosothiol Compounds and Related Derivatives
US20220387407A1 (en) Compositions and methods for attenuating opioid induced cardio and/or respiratory depression
US20220273604A1 (en) Compositions and methods for stimulating ventilatory and/or respiratory drive
CN110381934B (zh) 用于治疗睡眠呼吸障碍(sdb)的l-pag衍生物
Vadigeri A Prospective Randomised Comparative Study Of Efficacy And Safety Of Combination Of Inj. Dexmedetomidine–Propofol And Inj. Fentanyl-Propofol For The Insertion Conditions Of Proseal Laryngeal Mask Airway
EP4100010A1 (fr) Compositions et méthodes d'atténuation de la dépression cardio et/ou respiratoire induite par des opioïdes
Deodurg A Study Comparing Dexmedetomidine with Combination of Midazolam-Fentanyl for Middle Ear Surgeries Done Under Monitored Anesthesia Care
JP2022507733A (ja) 睡眠時無呼吸の治療のためのα２－アドレナリン受容体サブタイプＣ（α－２Ｃ）拮抗薬
WO2011074695A1 (fr) Suppresseur de tremblement

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12793690

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12793690

Country of ref document: EP

Kind code of ref document: A1